Silencing profilin-1 inhibits gastric cancer progression via integrin β1/focal adhesion kinase pathway modulation

Table 1 Correlation between profilin-1 expression and clinicopathological factors n (%)

Parameter	Cases	PFN1 expression		P value
		High expression	Low expression
Gender				0.073
Male	50	32 (60.4)	18 (81.8)
Female	25	21 (39.6)	4 (18.2)
Age (yr)				0.572
> 60	51	35 (66)	16 (72.7)
≤ 60	24	18 (34)	6 (27.3)
Location				0.457
Cardia	15	9 (60)	6 (40.0)
Corpus	26	18 (69.2)	8 (30.8)
Antrum	34	26 (76.5)	8 (23.5)
Size (diameter) (cm)				0.601
< 6	41	30 (56.6)	11 (50.0)
≥ 6	34	23 (43.4)	11 (50.0)
Differentiation
I and II	33	21 (39.6)	12 (54.5)	0.236
III and IV	42	32 (60.4)	10 (45.5)
Invasion depth
T0-T2	19	10 (18.9)	9 (41.0)	0.046
T3-T4	56	43 (81.1)	13 (59.0)
Nodal metastasis
Negative	27	15 (28.3)	12 (54.5)	0.038
Positive	48	38 (71.7)	10 (45.5)
TNM stage
I and II	29	16 (30.1)	13 (59.0)	0.036
III and IV	46	37 (69.9)	9 (41.0)
Total	75	53 (70.4)	22 (39.6)

PFN1: Profilin-1; TNM: Tumor-node-metastasis.